The use of the Er:YAG 2940nm laser associated with amorolfine lacquer in the treatment of onychomycosis.

Onychomycosis is a common disease, accounting for up to 50% of all ungual pathologies. We have been developing a clinical trial (ClinicalTrials.gov: NCT01528813) using a 2940nm Er:YAG laser to fractionally ablate human nails in vivo, aiming to increase topical amorolfine lacquer delivery to the nail unit, increasing the efficacy of topical treatment of distal and lateral subungual onychomycosis. Partial results have shown an increase in areas of nail plate free of disease. We believe that ablative lasers can increase the efficacy of topical onychomycosis treatment.

The use of the Er:YAG 2940nm laser associated with amorolfine lacquer in the treatment of onychomycosis / Uso do laser de Er:YAG 2940nm associado ao esmalte de amorolfina no tratamento da onicomicose

Onychomycosis is a common disease, accounting for up to 50% of all ungual pathologies. We have been developing a clinical trial (ClinicalTrials.gov: NCT01528813) using a 2940nm Er:YAG laser to fractionally ablate human nails in vivo, aiming to increase topical amorolfine lacquer delivery to the nail unit, increasing the efficacy of topical treatment of distal and lateral subungual onychomycosis. Partial results have shown an increase in areas of nail plate free of disease. We believe that ablative lasers can increase the efficacy of topical onychomycosis treatment.

A onicomicose é afecção frequente, representando até 50% do total das doenças ungueais. Um ensaio clinico (ClinicalTrials.gov: NCT01528813) em atual desenvolvimento usa o laser de Er:YAG 2940nm para realizar ablação fracionada in vivo de unhas humanas visando aumentar a permeabilidade ungueal ao esmalte de amorolfina, visando aumentar a eficácia do tratamento tópico da onicomicose subungueal distal lateral. Resultados parciais tem demonstrado um aumento na área ungueal livre de doença nas unhas tratadas com o laser, em comparação ao uso isolado do esmalte. Acreditamos que lasers ablativos possam aumentar a eficácia do tratamento tópico da onicomicose.